Elanco Animal Health INC Form 4 insider transactions

Jose Manuel Correia de Simas, an Executive Vice President at Elanco Animal Health, reports the acquisition of restricted stock units and stock options, as well as the disposition of shares to cover tax liabilities.

Interim General Counsel and Corporate Secretary Shiv O'Neill reports acquisition and disposal of Elanco Animal Health Inc. stock.

Elanco Animal Health's Executive Vice President, David S. Kinard, reports acquisition and disposal of common stock.

Elanco Animal Health Inc. CEO Jeffrey Simmons reports acquisition and disposal of common stock, resulting in adjustments to his direct and indirect beneficial ownership.

Todd S. Young, Executive Vice President and Chief Financial Officer of Elanco Animal Health Inc, reports changes in beneficial ownership of company stock, including acquisitions and disposals.

James M. Meer, Chief Accounting Officer of Elanco Animal Health Inc., reports acquisition of 2,483 shares and disposal of 854 shares of common stock on February 27, 2024.

EVP Grace McArdle reports acquisition of 2,033 shares and disposal of 1,089 shares of Elanco Animal Health Inc. stock.

Ellen de Brabander, Executive Vice President of Innovation and Regulatory Affairs at Elanco Animal Health Inc, reports changes in her beneficial ownership of company stock.

Jose Manuel Correia de Simas, an Executive Vice President at Elanco Animal Health, reports the acquisition and disposal of company stock.

Elanco Animal Health's Executive Vice President, Ramiro Martin Cabral, reports acquisition and disposal of common stock on February 27, 2024.

Elanco Animal Health's CEO, Jeffrey N. Simmons, reported the acquisition of deferred stock units, convertible to common stock, as per a recent SEC Form 4 filing.

Elanco Animal Health's Executive Vice President, Rajeev A. Modi, reports acquiring deferred stock units convertible to common stock or cash.